Pharma's Market
SPECIAL REPORT
MOST SHARED
- Realty Execs See Pain Ahead
- Want the Homebuyer's Tax Credit? Here Are Some Tips
- Tommy Lee, Medical Tourism and Nasty Santa, Your Emails
- Keith Bergelt: The Case for Market Based Patent Reform
- Gold Will Touch Higher Lows and Higher Highs: Analyst
- Buying Fear: How to Own Volatility
- Oil Next Week
- Buffett's Berkshire Hathaway Says Net Income Tripled
- Consumers Haven't Changed, They Are Just Pickier
- Can't Find a Job in Your Town? Here Are the Best Places to Look
- Tommy Lee, Medical Tourism and Nasty Santa, Your Emails
- U.S. Markets Gain 3% for the Week Despite 10.2% Unemployment
- Disney's 'Carol' Tests Widest 3-D Release Ever
- Stimulus II? Jobs Tax Credit=Cash For Clunkers
- Rockwell Automation Earnings: What Options Are Saying
- Gold Will Touch Higher Lows and Higher Highs: Analyst
- Is Misery Alive And Well in Your Office?
- Consumers Haven't Changed, They Are Just Pickier
- Watch Foreclosures, Seriously
- Outlook: Dollar Likely to Ride Higher on Bleak Jobs Report
- Buffett's Berkshire Hathaway Says Net Income Tripled
- Cramer: Earnings, IPOs Dominate Next Week
- Buying Fear: How to Own Volatility
- Administration Rejects Plan to Buy Fannie Mae Credits
- Consumers Haven't Changed —They Just Got Pickier
- Want the Homebuyer's Tax Credit? Here Are Some Tips
- Fears of Bubble Prompt Investors to Seek Exit Strategy
- Can't Find a Job? Here Are the Best Places to Look
RSS FEED
Text Size 
Reporter
 |
AP |
] could pay Warner Brothers enough money for Bugs' services. PLX also needs to first win FDA approval of its drug for the rare, genetic Gaucher disease. And today that's looking like it could happen sooner rather than later.Protalix announced this morning that the FDA has approached the company about possibly making the late-stage experimental drug available to certain patients under a special expanded access program before it's even formally approved. The agency is reacting to the recent setback suffered by biotech giant Genzyme [GENZ
Loading...
()
], which is having manufacturing issues at the plant that makes GENZ's very expensive, but widely used blockbuster Gaucher drug, Cerezyme. Apparently the agency is trying to avoid the impact of a potential shortage of treatments.
So, what's up with Bugs? Well, Protalix's drug is made with carrot proteins. No, it doesn't have a kibbutz (a communal farm) that grows the vegetable and a bunch of juicers churning 24/7 in its labs. It's all done with a proprietary technology the company owns to possibly make drugs with plant cell-based proteins from carrots and tobacco, too. Israel's Teva Pharmaceutical [TEVA
Loading...
()
], the world's biggest generic drug company, has partnered with Protalix on a couple of things based on the technology.
Shares of PLX are up nearly 200 percent so far this year and are rallying again today to a new intra-day high on the FDA news. And the volume is relatively huge. On an average day, only around 67,000 PLX shares change hands. As I write this more than a million shares have been traded. GENZ shares are getting dinged a little again.
That's all folks.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes